InterMune Inc.

New York, NY: (Mar-06-07) Patients with potentially fatal, idiopathic pulmonary fibrosis have been using a drug manufactured by InterMune Inc. The drug, Actimmune, was not approved for the disease, but had been promoted for that use by InterMune Inc. The federal government booked InterMune Inc. over allegations of promoting off-label use of Actimmune. The claims were settled with InterMune Inc. paying a fine of $36.9 million. InterMune has now announced that it was abandoning efforts to develop the product as a treatment for idiopathic pulmonary fibrosis because results from a late-stage clinical trial showed the drug did not prolong lives. The drug is already federally approved to treat two other rare conditions. [NEW YORK TIMES: OFF-LABEL ACTIMMUNE]

Legal Help

If you have a similar problem and would like to be contacted by a lawyer at no cost or obligation, please click the link below.
Published on Mar-9-07